Form 4: FRACTYL HEALTH, INC. Executive Jay David Caplan Reports Stock Sale

Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC., reported the sale of 65,000 shares of common stock on September 12, 2024, while also exercising options to acquire 95,484 shares.

Summary

• On September 12, 2024, Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC. (GUTS), executed transactions involving the company's common stock.
• Caplan exercised stock options to acquire 95,484 shares at a price of $1.70 per share.
• Simultaneously, Caplan sold 65,000 shares of common stock at a weighted average price of $2.8996, with individual sales ranging from $2.85 to $3.06 per share.
• Following these transactions, Caplan directly owns 30,484 shares and indirectly owns 358,806 shares through a trust and 118,810 shares through a family trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The sale of shares by an executive could be interpreted negatively, but the exercise of options suggests confidence. Without further context, it's difficult to assess the overall sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be scrutinized by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions provide transparency to stakeholders regarding insider trading activity.

Key Dates